PMID

Data

Article Title

Organization

Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR).

Exelixis

Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase.

Cephalon

A quantitative analysis of kinase inhibitor selectivity.

Ambit Biosciences

Comprehensive analysis of kinase inhibitor selectivity.

Ambit Biosciences

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).

Ambit Biosciences

Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550).

National Human Genome Research Institute

Characterization of a novel class of polyphenolic inhibitors of plasminogen activator inhibitor-1.

University Of Michigan

Discovery and design of novel HSP90 inhibitors using multiple fragment-based design strategies.

Abbott Laboratories